Discovering new cancer targets using advanced CRISPR technology
Bay Area Cancer Target Discovery and Development
This study is exploring new ways to find and target specific weaknesses in cancer cells using advanced CRISPR technology, with the hope of developing better treatments for people battling cancer.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10918329 on NIH RePORTER |
What this research studies
This research focuses on utilizing innovative CRISPR-based technologies to identify and characterize new targets for cancer treatment. By employing high-throughput methodologies, the team aims to uncover combinations of genetic targets that can effectively eliminate cancer cells, taking into account the complexity and diversity of tumors. The approach includes studying how different genes contribute to cancer development and resistance to therapies, using advanced techniques like single-cell analysis and lineage tracing. The ultimate goal is to find specific vulnerabilities in cancer cells that can be targeted for more effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with various types of cancer, particularly those who have shown resistance to current treatments.
Not a fit: Patients with benign tumors or those not diagnosed with cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that target the unique characteristics of individual tumors.
How similar studies have performed: Other research using CRISPR technology has shown promising results in identifying cancer targets, indicating that this approach has potential for success.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Mcmanus, Michael T — University of California, San Francisco
- Study coordinator: Mcmanus, Michael T
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.